Carl Dambkowski
Director Técnico/Científico/I+D en APOGEE THERAPEUTICS, INC. .
Fortuna: 4 M $ al 30/04/2024
Perfil
Carl Dambkowski is the founder of Novonate, Inc. (founded in 2015).
He is currently the Chief Medical Officer at Apogee Therapeutics, Inc. (since 2022).
Previously, he held the position of Chief Medical Officer at QED Therapeutics, Inc. (2021-2022), Chief Strategy Officer & EVP-Operations at Origin Biosciences, Inc. (2018-2021), Chief Medical Officer at Navire Pharma, Inc. (2020-2022), and Associate at McKinsey & Co., Inc. (2016-2018).
Dr. Dambkowski pursued his graduate degree at The Trustees of Columbia University in The City of New York and his undergraduate and doctorate degrees at Stanford University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 01/03/2024 | 95 979 ( 0.16% ) | 4 M $ | 30/04/2024 |
Cargos activos de Carl Dambkowski
| Empresas | Cargo | Inicio |
|---|---|---|
| APOGEE THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/09/2022 |
Antiguos cargos conocidos de Carl Dambkowski.
| Empresas | Cargo | Fin |
|---|---|---|
QED Therapeutics, Inc.
 QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Director Técnico/Científico/I+D | 01/09/2022 |
Navire Pharma, Inc.
 Navire Pharma, Inc. Pharmaceuticals: MajorHealth Technology Navire Pharma, Inc. engages in the development of therapeutics to treat multiple cancers. It focuses on SHP2, a protein-tyrosine phosphatase that links growth factor, cytokine and integrin signalling with the downstream RAS/ERK MAPK pathway to regulate cellular proliferation and survival. The company was founded by Phil Jones and Benjamin Neel in 2017 and is headquartered in San Francisco, CA. | Director Técnico/Científico/I+D | 01/09/2022 |
Origin Biosciences, Inc.
 Origin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., Origin Biosciences, Inc. is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The company is based in Palo Alto, CA. The company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector. Michael Henderson has been the CEO of the company since 2018. | Corporate Officer/Principal | 01/06/2021 |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/03/2018 |
Novonate, Inc.
 Novonate, Inc. Medical SpecialtiesHealth Technology Novonate, Inc. engages in designing products that solve problems in neonatal care. The company is headquartered in Palo Alto, CA. | Fundador | - |
Formación de Carl Dambkowski.
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| Stanford University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| APOGEE THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 5 |
|---|---|
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Novonate, Inc.
Novonate, Inc. Medical SpecialtiesHealth Technology Novonate, Inc. engages in designing products that solve problems in neonatal care. The company is headquartered in Palo Alto, CA. | Health Technology |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Health Technology |
Origin Biosciences, Inc.
Origin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., Origin Biosciences, Inc. is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The company is based in Palo Alto, CA. The company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector. Michael Henderson has been the CEO of the company since 2018. | Health Technology |
Navire Pharma, Inc.
Navire Pharma, Inc. Pharmaceuticals: MajorHealth Technology Navire Pharma, Inc. engages in the development of therapeutics to treat multiple cancers. It focuses on SHP2, a protein-tyrosine phosphatase that links growth factor, cytokine and integrin signalling with the downstream RAS/ERK MAPK pathway to regulate cellular proliferation and survival. The company was founded by Phil Jones and Benjamin Neel in 2017 and is headquartered in San Francisco, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Carl Dambkowski
